Oral treatment of fungal infections of the oropharynx and gastrointestinal tract.
Miconazole gel is for use in adults, children and infants 4 months and older.

For oral administration.
Oropharyngeal candidosis
Infants: 4-24 months: 1.25 mL (1/4 measuring spoon; equivalent to approximately 25 mg) of gel, applied four times a day after meals. Each dose should be divided into smaller portions and the gel should be applied to the affected area(s) with a clean finger. The gel should not be applied to the back of the throat due to possible choking.
The gel should not be swallowed immediately, but kept in the mouth as long as possible.
Adults and children 2 years of age and older: 2.5 mL (1/2 measuring spoon; equivalent to approximately 50 mg) of gel, applied four times a day after meals.

The gel should not be swallowed immediately, but kept in the mouth as long as possible.
The treatment should be continued for at least a week after the symptoms have disappeared.
For oral candidosis, dental prostheses should be removed at night and brushed with the gel.
Gastrointestinal tract candidosis
The gel may be used for infants (≥ 4 months of age), children, and adults who have difficulty swallowing tablets. The dosage is 20 mg per kg body weight per day, administered in four divided doses. The daily dose should not exceed 250 mg (10 mL Oral Gel) four times a day.
The treatment should be continued for at least a week after the symptoms have disappeared

Known hypersensitivity to miconazole, other imidazole derivatives or to any of the excipients listed in section 6.1. In infants less than 4 months of age or in those whose swallowing reflex is not yet sufficiently developed (see section 4.4) In patients with liver dysfunction. Coadministration of the following drugs that are subject to metabolism by CYP3A4: (See Section 4.5 Interactions with Other Medicinal Products and Other Forms of Interaction) - Substrates known to prolong the QT-interval e.g., astemizole, cisapride, dofetilide, mizolastine, pimozide, quinidine, sertindole and terfenadine - Ergot alkaloids - HMG-CoA reductase inhibitors such as simvastatin and lovastatin - Triazolam and oral midazolam

If the concomitant use of Mycoheal® and anticoagulants is envisaged, the anticoagulant effect should be carefully monitored and titrated (see section 4.5).
Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported during treatment with miconazole and with other miconazole formulations (see section 4.8). If a reaction suggesting hypersensitivity or irritation should occur, the treatment should be discontinued.
It is advisable to monitor miconazole and phenytoin levels, if these two drugs are used concomitantly.
In patients using certain oral hypoglycaemics such as sulphonylureas, an enhanced therapeutic effect leading to hypoglycaemia may occur during concomitant treatment with miconazole and appropriate measures should be considered (See Section 4.5 Interactions with Other Medicinal Products and Other Forms of Interaction).
Choking in infants and young children
Particularly in infants and young children (aged 4 months – 2 years), caution is required, to ensure that the gel does not obstruct the throat. Hence, the gel should not be applied to the back of the throat. Each dose should be divided into smaller portions and applied into the mouth with a clean finger. Observe the patient for possible choking. Also due to the risk of choking, the gel must not be applied to the nipple of a breast-feeding woman for administration to an infant.
It is important to take into consideration the variability of the maturation of the swallowing function in infants, especially when giving miconazole gel to infants between the ages of 4-6 months. The lower age limit should be increased to 5-6 months of age for infants who are pre-term, or infants exhibiting slow neuromuscular development.
Serious skin reactions (e.g. Toxic epidermal necrolysis and Stevens-Johnson syndrome) have been reported in patients receiving miconazole oral gel (see section 4.8). It is recommended that patients be informed about the signs of serious skin reactions, and that use of miconazole oral gel be discontinued at the first appearance of skin rash.

When using any concomitant medication the corresponding label should be consulted for information on the route of metabolism. Miconazole can inhibit the metabolism of drugs metabolized by the CYP3A4 and CYP2C9 enzyme systems. This can result in an increase and/or prolongation of their effects, including adverse effects.
Oral miconazole is contraindicated with the coadministration of the following drugs that are subject to metabolism by CYP3A4 (See Section 4.3 Contraindications):
- Substrates known to prolong the QT-interval e.g., astemizole, cisapride, dofetilide, mizolastine, pimozide, quinidine, sertindole and terfenadine
- Ergot alkaloids
- HMG-CoA reductase inhibitors such as simvastatin and lovastatin
- Triazolam and oral midazolam
When coadministered with oral miconazole the following drugs should be used with caution because of a possible increase or prolongation of the therapeutic outcome and/or adverse events. If necessary, their dosage should be reduced and, where appropriate, plasma levels monitored:
Drugs subject to metabolism by CYP2C9 (see Section 4.4 Special Warnings and Precautions for Use);
- Oral anticoagulants such as warfarin
- Oral hypoglycaemics such as sulphonylureas
- Phenytoin
Other drugs subject to metabolism by CYP3A4;
- HIV Protease Inhibitors such as saquinavir;
- Certain antineoplastic agents such as vinca alkaloids, busulfan and docetaxel;
- Certain calcium channel blockers such as dihydropyridines and verapamil;
- Certain immunosuppressive agents: cyclosporin, tacrolimus, sirolimus (= rapamycin)
- Others: carbamazepine, cilostazol, disopyramide, buspirone, alfentanil, sildenafil, alprazolam, brotizolam, midazolam IV, rifabutin, methylprednisolone, trimetrexate, ebastine and reboxetine.

Pregnancy category: C.
In animals, miconazole has shown no teratogenic effects but is foetotoxic at high oral doses. The significance of this to man is unknown. However, as with other imidazoles, Mycoheal ® Oral Gel should be avoided in pregnant women if possible. The potential hazards should be balanced against the possible benefits.
It is not known whether miconazole is excreted in human milk. Caution should be exercised when prescribing Mycoheal ® Oral Gel to nursing mothers.

Mycoheal ® should not affect alertness or driving ability.

The safety of miconazole Oral Gel was evaluated in 111 patients with oral candidiasis or oral mycoses who participated in 5 clinical trials. Of these 111 patients, 88 were adults with oral candidiasis or oral mycoses who participated in 1 randomised, active-controlled, double-blind clinical trial and 3 open-label clinical trials. The other 23 patients were paediatric patients with oral candidiasis who participated in 1 randomised, active-controlled, open-label clinical trial in paediatric patients (aged ≤1 month to 10.7 years). These patients took at least one dose of miconazole Oral Gel and provided safety data.
Based on the pooled safety data from these 5 clinical trials (adult and paediatric), the most commonly reported (≥1% incidence) adverse reactions were nausea (6.3%), product taste abnormal (3.6%), vomiting (3.6%), oral discomfort (2.7%), regurgitation (1.8%), and dry mouth (1.8%). Dysgeusia was reported in 0.9% of patients.
Adult Patients
Based on the pooled safety data from the 4 clinical trials in adults, common adverse reactions reported included nausea (4.5%), product taste abnormal (4.5%), oral discomfort (3.4%), dry mouth (2.3%), dysgeusia (1.1%), and vomiting (1.1%).
Paediatric Patients
In the 1 paediatric clinical trial, the frequency of nausea (13.0%) and vomiting (13.0%) was very common, and regurgitation (8.7%) was common. As identified through post-marketing experience, choking may occur in infants and young children (See Section 4.3 Contraindications and Section 4.4 Special Warnings and Special Precautions). The frequency, type, and severity of other adverse reactions in children are expected to be similar to that in adults.
Table A includes all identified adverse reactions, including those that that have been reported from post-marketing experience.
The frequency categories use the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available clinical trial data).
Table A: Adverse Drug Reactions in Patients Treated with Miconazole Oral Gel

The safety of miconazole Oral Gel was evaluated in 111 patients with oral candidiasis or oral mycoses who participated in 5 clinical trials. Of these 111 patients, 88 were adults with oral candidiasis or oral mycoses who participated in 1 randomised, active-controlled, double-blind clinical trial and 3 open-label clinical trials. The other 23 patients were paediatric patients with oral candidiasis who participated in 1 randomised, active-controlled, open-label clinical trial in paediatric patients (aged ≤1 month to 10.7 years). These patients took at least one dose of miconazole Oral Gel and provided safety data. Based on the pooled safety data from these 5 clinical trials (adult and paediatric), the most commonly reported (≥1% incidence) adverse reactions were nausea (6.3%), product taste abnormal (3.6%), vomiting (3.6%), oral discomfort (2.7%), regurgitation (1.8%), and dry mouth (1.8%). Dysgeusia was reported in 0.9% of patients. Adult Patients Based on the pooled safety data from the 4 clinical trials in adults, common adverse reactions reported included nausea (4.5%), product taste abnormal (4.5%), oral discomfort (3.4%), dry mouth (2.3%), dysgeusia (1.1%), and vomiting (1.1%). Paediatric Patients In the 1 paediatric clinical trial, the frequency of nausea (13.0%) and vomiting (13.0%) was very common, and regurgitation (8.7%) was common. As identified through post-marketing experience, choking may occur in infants and young children (See Section 4.3 Contraindications and Section 4.4 Special Warnings and Special Precautions). The frequency, type, and severity of other adverse reactions in children are expected to be similar to that in adults. Table A includes all identified adverse reactions, including those that that have been reported from post-marketing experience. The frequency categories use the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available clinical trial data).   Table A: Adverse Drug Reactions in Patients Treated with Miconazole Oral Gel System Organ Class Adverse Drug Reactions Frequency Category Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to <1/100) Not Known Immune System Disorders     Anaphylactic reaction, Hypersensitivity Nervous System Disorders   Dysgeusia   Respiratory, Thoracic and Mediastinal Disorders     Choking Gastrointestinal Disorders Dry mouth, Nausea, Oral discomfort, Vomiting, Regurgitation   Diarrhoea, Stomatitis, Tongue discolouration Hepatobiliary Disorders     Hepatitis Skin and Subcutaneous Tissue Disorders     Angioedema, Toxic epidermal necrolysis, Stevens-Johnson syndrome, Urticaria, Rash, Acute generalised exanthematous pustulosis, Drug reaction with eosinophilia and systemic symptoms Skin and Subcutaneous Tissue Disorders     Toxic epidermal necrolysis, Stevens-Johnson syndrome, Urticaria, Rash, Acute generalised exanthematous pustulosis, Drug reaction with eosinophilia and systemic symptoms General Disorders and Administration Site Conditions Product taste abnormal

Symptoms:
In the event of accidental overdose, vomiting and diarrhoea may occur.
Treatment:
Treatment is symptomatic and supportive. A specific antidote is not available.

ATC Code: A01A B09 and A07A C01
Miconazole possesses an antifungal activity against the common dermatophytes and yeasts as well as an antibacterial activity against certain gram-positive bacilli and cocci.
Its activity is based on the inhibition of the ergosterol biosynthesis in fungi and the change in the composition of the lipid components in the membrane, resulting in fungal cell necrosis.

Absorption:
Miconazole is systemically absorbed after administration as the oral gel. Administration of a 60 mg dose of miconazole as the oral gel results in peak plasma concentrations of 31 to 49 ng/mL, occurring approximately two hours post-dose.
Distribution:
Absorbed miconazole is bound to plasma proteins (88.2%), primarily to serum albumin and red blood cells (10.6%).
Metabolism and Elimination:
The absorbed portion of miconazole is largely metabolized; less than 1% of an administered dose is excreted unchanged in the urine. The terminal half-life of plasma miconazole is 20 to 25 hours in most patients. The elimination half-life of miconazole is similar in renally impaired patients. Plasma concentrations of miconazole are moderately reduced (approximately 50%) during hemodialysis. About 50% of an oral dose may be excreted in the faeces partly metabolized and partly unchanged.

Preclinical data reveal no special hazard for humans based on conventional studies of local irritation, single and repeated dose toxicity, genotoxicity, and toxicity to reproduction.

Glycerol, polysorbate 20, carbomer, saccharin, triethanolamine, banana liquid and purified water.

None known.

36 months.

Do not store above 30 °C.
Discard unused content 7 days after first breaking tube seal.

Mycoheal® Oral gel is available in collapsible aluminum tube that contains 40 gm of the gel along with plastic spoon.
Immediate packaging: collapsible aluminum tube
Outer packaging: Carboard box, insert with a plastic spoon.

Not Applicable